G.I. Windows is a technology company.
GI Windows Surgical uses a novel approach to create a magnetic anastomosis that forms an immediately patent lumen, showing superior healing compared to traditional staplers.
G.I. Windows has raised $68.0M across 3 funding rounds.
G.I. Windows has raised $68.0M in total across 3 funding rounds.
G.I. Windows has raised $68.0M in total across 3 funding rounds.
G.I. Windows's investors include Lux Capital, Sonder Capital, Threshold Ventures.
G.I. Windows is a clinical-stage medical device company specializing in innovative anastomosis technology, specifically magnetic compression anastomosis designed to enable less invasive gastrointestinal surgeries. Their technology aims to improve surgical outcomes by enhancing safety, accelerating healing, and reducing post-surgical complications, serving surgeons and patients in the GI tract surgery space. The company has demonstrated strong growth momentum through significant venture funding rounds totaling over $53 million and FDA Breakthrough Device designation, underscoring its clinical promise and market potential[1][2][3].
Founded in 2012 and headquartered in Massachusetts, G.I. Windows was spun out of Beacon Endoscopic (acquired by Covidien in 2014). The founding team leveraged prior expertise in endoscopic technologies to develop a novel magnetic anastomosis device that simplifies tissue fusion and delivery during surgery. Early pivotal moments include securing substantial Series A-1 funding in 2020 from strategic investors such as Johnson & Johnson Innovation and Sonder Capital, and receiving FDA Breakthrough Device status, which accelerates regulatory review and highlights the technology’s potential impact on patient care[1][2][3].
G.I. Windows rides the trend toward minimally invasive surgical technologies that improve patient outcomes and reduce healthcare system burdens. The timing is favorable due to increasing demand for safer, faster recovery procedures and advances in medical device innovation. Their magnetic anastomosis technology addresses a critical need in gastrointestinal surgery by offering a fundamentally new approach to tissue joining, which could influence surgical standards and enable new procedures. This positions G.I. Windows as a key player in the evolving ecosystem of surgical innovation and medical device development.
Looking ahead, G.I. Windows is poised to advance through ongoing clinical trials and regulatory milestones, potentially expanding indications beyond small bowel applications. Trends such as personalized medicine, enhanced surgical robotics integration, and value-based healthcare will shape their trajectory. As they move toward commercialization, their influence may grow by setting new benchmarks in surgical safety and efficiency, ultimately reshaping GI surgery practices and improving patient care on a broad scale. Their continued success will depend on clinical validation, regulatory approvals, and adoption by the surgical community, tying back to their mission of revolutionizing anastomotic procedures.
G.I. Windows has raised $68.0M across 3 funding rounds. Most recently, it raised $37.0M Series B in November 2024.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Nov 1, 2024 | $37.0M Series B | Lux Capital, Sonder Capital, Threshold Ventures | |
| Aug 1, 2020 | $16.0M Series A | Sonder Capital | |
| Dec 1, 2019 | $15.0M Series A | Sonder Capital |